Fomes fomentarius and tricholoma anatolicum (Agaricomycetes) extracts exhibit significant multiple drug-resistant modulation activity in drug-resistant breast cancer cells

Basit Öğe Kaydı
dc.contributor.authorDoğan H.H.
dc.contributor.authorKars M.D.
dc.contributor.authorÖzdemir Ö.
dc.contributor.authorGündüz U.
dc.date.accessioned2020-03-26T20:20:48Z
dc.date.available2020-03-26T20:20:48Z
dc.date.issued2020
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractMultiple drug resistance is one of the main problems that hinder successful cancer chemotherapy. Investigations on the development of effective chemotherapeutic agents and drug resistance inhibitors motivate studies on the effects of natural compounds on drug-resistant cancer cells. For this purpose, aqueous, methanol, and ethanol extracts of Fomes fomentarius and Tricholoma anatolicum were prepared. The extracts were evaluated to assess their anticancer and multiple drug resistance modulation activities. Cytotoxic effects of F. fomentarius and T. anatolicum extracts on paclitaxel and vincristine resistant P-glycoprotein over-expressing MCF-7 cell lines were investigated by cytotoxicity test (XTT). P-glycoprotein reversing ability and MDR modulation effects of the extracts were determined by flow cytometry through Rhodamine 123 exclusion assay. Furthermore, 11 phenolic compounds in the extracts were characterized by HPLC. As a result of the cytotoxicity assay, IC50 values of the extracts for MCF-7/Vinc were between 1.08 and 1.80 mg/ mL, and IC50 values for MCF-7/Pac were found between 1.11 and 2.83 mg/mL. Strikingly, methanol extract of F. fomentarius and ethanol extract of T. anatolicum have potential value to become MDR reversing agents for drug-resistant breast cancer cells. © 2020 by Begell House.en_US
dc.description.sponsorshipMinisterio de Fomento KBAG-113Z467, BAP-13401138en_US
dc.description.sponsorshipThis study was supported by a TUBITAK project (KBAG-113Z467) and S.U. Scientific Research Project (BAP-13401138). HPLC and flow cytometry facilities were funded by Ministry of Development with the Project No. DPT_2009K121080.en_US
dc.identifier.doi10.1615/IntJMedMushrooms.2020033174en_US
dc.identifier.endpage114en_US
dc.identifier.issn1521-9437en_US
dc.identifier.issue2en_US
dc.identifier.pmid32478999en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage105en_US
dc.identifier.urihttps://dx.doi.org/10.1615/IntJMedMushrooms.2020033174
dc.identifier.urihttps://hdl.handle.net/20.500.12395/38673
dc.identifier.volume22en_US
dc.identifier.wosWOS:000520021000001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBegell House Inc.en_US
dc.relation.ispartofInternational Journal of Medicinal Mushroomsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAntitumor effecten_US
dc.subjectFomes fomentariusen_US
dc.subjectMDR reversalen_US
dc.subjectMedicinal mushroomsen_US
dc.subjectTricholoma anatolicumen_US
dc.titleFomes fomentarius and tricholoma anatolicum (Agaricomycetes) extracts exhibit significant multiple drug-resistant modulation activity in drug-resistant breast cancer cellsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu